0000000000685820

AUTHOR

Francesco Bertagna

0000-0003-2980-5964

showing 2 related works from this author

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A pros…

2015

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p < 0.0001).…

medicine.medical_specialtyCancer ResearchMultivariate analysisLymphomaChemotherapeutic approaches; Immunotherapy; Lymphoma and Hodgkin disease; Hematology; Oncology; Cancer ResearchMEDLINEDisease-Free SurvivalInternal medicineComprehensive Assesment Diffuse large B cell lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicine80 and overLarge B-CellHumansProspective StudiesProspective cohort studyGeriatric AssessmentAgedAged 80 and overChemotherapeutic approachesbusiness.industryPalliative CareGeriatric assessmentHematologymedicine.diseasePrognosisDiffuseSurgeryLymphomaSettore MED/15 - MALATTIE DEL SANGUETreatment OutcomeMulticenter studyOncologyLymphoma and Hodgkin diseaseMultivariate AnalysisTreatment decision makingImmunotherapyLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience.

2020

Objectives: Solitary plasmacytoma (SP) is characterized by a single mass of clonal plasma cells. Definitive RT can result in long-term local control of the SP. Due to the small number of patients and narrow range of doses, phase III randomized trials are lacking. The aim of this study is to further support the potential use of RT for the treatment of SP. Methods: Clinical data of all patients treated for SP at our Institution between 1992 and 2018 were reviewed. A total of 42 consecutive patients were analyzed. Results: The median follow-up was 84.8 months. Radiation dose did not differ significantly as a function of sex, type of SP (solitary bone plasmacytoma or as extramedullary plasmacyt…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologySolitary plasmacytomaBone NeoplasmsMultiple myeloma; Plasma cell neoplasms; Radical radiotherapy; Solitary plasmacytomaEffective dose (radiation)law.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansMultiple myelomaAgedRetrospective StudiesAged 80 and overHematologyRadical radiotherapyTumor sizebusiness.industryGeneral MedicinePlasma cell neoplasmMiddle Agedmedicine.diseasePrognosisSurvival AnalysisRadiation therapyPlasma cell neoplasm030104 developmental biologyTreatment OutcomeOncologyItaly030220 oncology & carcinogenesisDisease ProgressionFemalePlasma cell neoplasmsNeoplasm Recurrence LocalbusinessMultiple MyelomaSolitary plasmacytomaFollow-Up StudiesPlasmacytomaJournal of cancer research and clinical oncology
researchProduct